July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Mark Wildgust: First Results from Janssen’s Pasritamig – A Breakthrough Bispecific T-Cell Engager for mCRPC
Jun 4, 2025, 08:32

Mark Wildgust: First Results from Janssen’s Pasritamig – A Breakthrough Bispecific T-Cell Engager for mCRPC

Mark Wildgust, Vice President, Global Medical Affairs, Oncology at The Janssen Pharmaceutical Companies of Johnson and Johnson, shared a post on X:

“Excited to share the first results from our ⁦Johnson & Johnson Innovation⁩ new KLK2xCD3 investigational agent called pasritamig, a first-in-class, Bispecific T-Cell Engager Targeting Human Kallikrein 2 (KLK2) in mCRPC.”

Title: Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study

Authors: Mark N. Stein, Armelle Vinceneux, Debbie Robbrecht, Bernard Doger, Karen A. Autio, Michael T. Schweizer, Emiliano Calvo, Laura Medina, Marloes Van Dongen, Jean-Laurent Deville, Alice Bernard-Tessier, Debopriya Ghosh, Kristin Shotts, Fei Shen, Pharavee Jaiprasart, Ruchi Chaudhary, Shujian Wu, Leanne Cartee, Robert Schnepp, Daria Gaut, Josh Lauring, Sherry C. Wang, Victor M. Villalobos, Capucine Baldini.

Read the Full Article on Journal of Clinical Oncology.

Mark Wildgust